Please assess the completion status of the following clinical trial:

Trial Title: Stereotactic Radiosurgery After Surgery in Treating Patients With Brain Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>18 years of age.~2. Gross total resection (as verified by the lack of any enhancement in the resection cavity on post-operative MRI) of single brain metastasis confirmed by histology. Patients with up to 4 metastases are eligible if the largest mass is amenable to surgical resection and all non-resected masses are amenable to SRS.~3. Patient must be Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis (RPA) Class 1 or 2.~4. Life expectancy of at least 3 months.~Exclusion Criteria:~1. Radiographic or cytologic evidence of leptomeningeal disease.~2. Patient with incomplete or partial resection.~3. Primary lesion with radiosensitive histology (i.e., small cell carcinoma, germ-cell tumors, lymphoma, leukemia, and multiple myeloma).~4. Patients with a resection cavity \> 4 cm in maximal extent in any plane on contrasted MRI scan.~5. Lesion located in anatomic regions which are not amenable to SRS including the brain stem and optic apparatus.~6. Pregnant or need to breast feed during the study period.~7. Uncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness.~8. Brain surgery other than for resection of metastasis.~9. Previous brain radiotherapy.~10. Contraindication to SRS, WBRT, or MRI.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Post-operative SRS (Type: ACTIVE_COMPARATOR): All patients will undergo SRS with the planned target volume (PTV) defined as the resection cavity plus a 3-mm margin after surgical resection of a single brain metastasis. Dose will be prescribed to the maximum isodose line completely encompassing the PTV using the guidelines established in RTOG 9005. All patients will be evaluated for neurocognitive function via Mini-Mental State Examination (MMSE), Quality of Life (QOL) via FACT-Br, and for local recurrence via MRI every 3 months over the course of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).